Therefore, the results of this trial suggested a possible role for the use of ABT-414 in combination with temozolomide in EGFR amplified recurrent GBM, especially in patients relapsing after completing 6 cycles of maintenance temozolomide. This evidence concerns the gene EGFR and glioblastoma.